Key Points
- Medpace General Counsel Stephen Ewald sold 16,349 shares at an average price of $450 each, totaling about $7.36 million. After the sale, he still held 20,343 shares, according to the SEC filing.
- Medpace shares rose 1.0% and opened at $451.47, near the $450 sale price. The stock remains well below its 52-week high of $628.92 but above its 52-week low of $291.28.
- The company recently posted stronger-than-expected quarterly results, with EPS of $4.28 beating estimates and revenue up 26.5% year over year. However, analysts are mixed overall, with the consensus rating at Hold and recent lawsuit-related headlines adding legal overhang.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) General Counsel Stephen Ewald sold 16,349 shares of the company's stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Medpace Stock Up 1.0%
Shares of MEDP opened at $451.47 on Tuesday. Medpace Holdings, Inc. has a 12-month low of $291.28 and a 12-month high of $628.92. The firm has a market capitalization of $12.89 billion, a PE ratio of 28.38, a price-to-earnings-growth ratio of 2.27 and a beta of 1.19. The stock's fifty day simple moving average is $457.28 and its 200-day simple moving average is $512.30.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the prior year, the firm posted $3.67 earnings per share. The firm's revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.
Institutional Investors Weigh In On Medpace
Large investors have recently modified their holdings of the business. Optiver Holding B.V. bought a new stake in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace in the fourth quarter worth about $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace in the fourth quarter worth about $30,000. Finally, Quarry LP bought a new stake in shares of Medpace in the third quarter worth about $35,000. 77.98% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the company. Mizuho set a $582.00 price target on Medpace in a research note on Wednesday, February 11th. Leerink Partners cut their target price on Medpace from $575.00 to $485.00 and set a "market perform" rating on the stock in a research note on Wednesday, February 11th. Barclays cut their target price on Medpace from $500.00 to $450.00 and set an "equal weight" rating on the stock in a research note on Friday, April 24th. Robert W. Baird cut their target price on Medpace from $565.00 to $477.00 and set an "outperform" rating on the stock in a research note on Friday, April 24th. Finally, Weiss Ratings lowered Medpace from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, April 6th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $467.08.
Read Our Latest Analysis on MEDP
Trending Headlines about Medpace
Here are the key news stories impacting Medpace this week:
- Negative Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Levi & Korsinsky, the Schall Law Firm, DJS Law Group, and others, reminded investors that a class action has been filed against Medpace and certain officers, keeping legal overhang and potential liability in focus. Article: MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit
- Negative Sentiment: The lawsuit reminders may reinforce concerns that Medpace could face damages, legal costs, or reputational pressure if the allegations gain traction. Article: MEDP Investor Alert: Medpace Holdings Inc. Securities Fraud Lawsuit
- Neutral Sentiment: One disclosed insider transaction showed Medpace General Counsel Stephen P. Ewald sold 16,349 shares at $450 each, a move that may draw investor attention but does not by itself establish a broader business trend. Article: SEC Form 4 filing for Stephen P. Ewald
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
